The independent vaccine advisors to the Centers for Disease Control and Prevention of the United States decided Wednesday unanimously in favor of the two-dose Jynneos mpox vaccine for people that are at risk of getting the disease during an epidemic.
If the CDC agrees with the committee's proposal, there will be a suggestion to provide the vaccination to those at risk for mpox epidemics in the future.
Since the outbreak's height in August, the number of new cases of mpox, formerly known as monkeypox, has decreased dramatically in the United States. The current seven-day average indicates that there are still two new cases each day, compared to approximately 450 instances per day in August; yet, two cases is more than in past years, according to specialists.
Dr. Jamie Loehr, proprietor of Cayuga Family Medicine in Ithaca, New York, and a committee member, stated, "We have a highly potent vaccination." "We've got good data and if my calculations are true, it actually has a relatively high fatality rate. That is approximately 1 in 1,000, which is a considerable death rate. Hence, I am strongly in support of this," Loehr continued.
The 18 members voted in support of the vaccine recommendation: "ACIP recommends the 2-dose Jynneos vaccine course for persons 18 years of age and older who are at risk of mumps outbreaks."
In 2021, during the height of the outbreak in August, the vaccine was authorized for emergency use to prevent future sickness. More than 1.18 million Jynneos vaccinations have been delivered in the United States.
Although the vaccine's efficacy was never shown in clinical trials for mpox, investigations conducted during the outbreak revealed that it was up to 83 percent effective, according to the CDC..
According to a CDC presentation, the incidence of Mpox among unvaccinated individuals was 7.4 times higher than among those who had received one dose of Jynneos vaccination and 9.6 times higher than among those who had received two doses of Jynneos vaccine. There were no unanticipated or new safety issues with the vaccine. Severe adverse effects were uncommon among adults. The immunization did not appear to increase the risk of myocarditis or pericarditis. The most complaints were injection site redness and tiredness. The CDC urges anyone at risk to get vaccinated.
During the most recent outbreak of mpox, the United States dominated the world with over 30,000 illnesses and cases throughout all 50 states. Members of the gay and bisexual community, as well as other men who have sex with men, accounted for 95% of reported cases. Almost one-third of the total cases were documented among Black, Hispanic, and White individuals.
Also, sexually active individuals appeared to be the primary carriers of the virus. 75% of cases for which the CDC had sexual history information reported having sex or close contact with another person three weeks before the onset of symptoms.
Dr. Melinda Wharton, Associate Director for Vaccine Policy at the Centers for Disease Control and Prevention, stated, "The recent outbreak has highlighted the risks that infectious diseases pose to our communities, the importance of a robust public health response at the state and local level, the value of engaged partners and communities in responding to public health threats, and the impact that a vaccine can have in helping to bring an outbreak under control."